Similar articles

• [Characteristics of the effects of de-nol on the course of erosive-ulcerative lesions of the esophagus, stomach and duodenum associated with Helicobacter pylori].

  Grebenev AL, Miagkova LP, Golochevskaia VS, Lapina TL, Sklianskaia OA. Grebenev AL, et al. Klin Med (Mosk). 1995;73(2):34-7. Klin Med (Mosk). 1995. PMID: 7609414 Russian. No abstract available.
• Colloidal bismuth subcitrate in peptic ulcer disease.

  Tytgat GN. Tytgat GN. S Afr Med J. 1986 Jul 5;70(1):31-3. S Afr Med J. 1986. PMID: 3523793 Clinical Trial.
• Peptic ulcer treatment today--is there a role for maintenance therapy?

  Breslin NP, O'Morain C. Breslin NP, et al. Ital J Gastroenterol Hepatol. 1997 Apr;29(2):116-21. Ital J Gastroenterol Hepatol. 1997. PMID: 9646190 No abstract available.
• Sucralfate, bismuth compounds, substituted benzimidazoles, trimipramine and pirenzepine in the short- and long-term treatment of duodenal ulcer.

  Tytgat GN, Hameeteman W, van Olffen GH. Tytgat GN, et al. Clin Gastroenterol. 1984 May;13(2):543-68. Clin Gastroenterol. 1984. PMID: 6378446 Review. No abstract available.
• The pharmacology of peptic ulcer disease.

  Ippoliti A, Peterson W. Ippoliti A, et al. Clin Gastroenterol. 1979 Jan;8(1):53-67. Clin Gastroenterol. 1979. PMID: 369747 Review. No abstract available.